GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Steris PLC (NYSE:STE) » Definitions » EV-to-EBITDA

Steris (Steris) EV-to-EBITDA : 17.11 (As of May. 05, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Steris EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Steris's enterprise value is $23,849 Mil. Steris's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $1,394 Mil. Therefore, Steris's EV-to-EBITDA for today is 17.11.

The historical rank and industry rank for Steris's EV-to-EBITDA or its related term are showing as below:

STE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.04   Med: 18.87   Max: 38.41
Current: 17.11

During the past 13 years, the highest EV-to-EBITDA of Steris was 38.41. The lowest was 9.04. And the median was 18.87.

STE's EV-to-EBITDA is ranked worse than
52.48% of 484 companies
in the Medical Devices & Instruments industry
Industry Median: 16.065 vs STE: 17.11

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Steris's stock price is $207.82. Steris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $5.710. Therefore, Steris's PE Ratio for today is 36.40.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Steris EV-to-EBITDA Historical Data

The historical data trend for Steris's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steris EV-to-EBITDA Chart

Steris Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.42 17.47 23.06 28.35 26.72

Steris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.37 26.72 29.52 18.41 17.97

Competitive Comparison of Steris's EV-to-EBITDA

For the Medical Devices subindustry, Steris's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steris's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Steris's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Steris's EV-to-EBITDA falls into.



Steris EV-to-EBITDA Calculation

Steris's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=23848.999/1394.017
=17.11

Steris's current Enterprise Value is $23,849 Mil.
Steris's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,394 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steris  (NYSE:STE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Steris's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=207.82/5.710
=36.40

Steris's share price for today is $207.82.
Steris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.710.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Steris EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Steris's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Steris (Steris) Business Description

Traded in Other Exchanges
Address
5960 Heisley Road, Mentor, OH, USA, 44060
Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.
Executives
Richard C Breeden director 100 SOUTH WACKER, SUITE 1800, CHICAGO IL 60606
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Jacqueline B Kosecoff director 5960 HEISLEY ROAD, MENTOR OH 44060
Mohsen Sohi director C/O STERIS CORPORATION, 5960 HEISLEY ROAD, MENTOR OH 44060
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Cary L Majors officer: VP, N America Com Operations 5960 HEISLEY ROAD, MENTOR OH 44060
John Adam Zangerle director, officer: Sr. VP, Gen Counsel, and Sec. 5960 HEISLEY ROAD, MENTOR OH 44060
Michael J Tokich director, officer: Sr. Vice Pres., CFO C/O STERIS CORP, 5960 HEISLEY RD, MENTOR OH 44060
Karen L Burton officer: VP, Controller & CAO 5960 HEISLEY ROAD, MENTOR OH 44060
Renato Tamaro officer: V.P. & Corporate Treasurer 5960 HEISLEY ROAD, MENTOR OH 44060
Andrew Xilas officer: SVP and GM, Dental 5960 HEISLEY ROAD, MENTOR OH 44060
Paul Edward Martin director C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Julia Madsen officer: Senior VP, Life Sciences 5960 HEISLEY ROAD, MENTOR OH 44060
David B Lewis director
Rosebrough Walter M Jr officer: President & CEO 5960 HEISLEY ROAD, MENTOR OH 44060